Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The available evidence on PEG-MGF is extremely limited. A 2026 review in Frontiers in Endocrinology examined performance-enhancing peptides that affect the growth hormone-IGF1 pathway, including PEG-MGF, but this appears to be primarily a landscape review rather than original research providing specific clinical data on PEG-MGF's safety or efficacy.
One clinical trial (NCT02375620) is studying a related compound - pegylated somatropin (PEG Somatropin) - in children with short stature born small for gestational age. This Phase 2 trial is currently active but not recruiting new participants. However, this study involves pegylated growth hormone rather than PEG-MGF specifically, so its findings may not directly translate to PEG-MGF.
Evidence Gap: There is a notable lack of published clinical trials, controlled studies, or peer-reviewed research specifically investigating PEG-MGF's safety, efficacy, pharmacokinetics, or clinical applications in humans. The existing evidence base is insufficient to draw meaningful conclusions about this compound's therapeutic potential or safety profile.
This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare provider before considering any experimental or unapproved treatments.